IRIDEX Stock

IRIDEX EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of IRIDEX (IRIX) as of Aug 18, 2026 is -8.96. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.77 — a change of 222.91% (lower).

EV/EBIT

-8.96

YoY

222.91%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IRIDEX is 2026 -8.96 . EV/EBIT (Enterprise Value to EBIT) of IRIDEX was 2025 -2.77 . It decreases by 222.91% lower compared to the previous year.

The IRIDEX EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-3.43 base
Jan 1, 2020
-5.30 base
Jan 1, 2021
-12.87 base
Jan 1, 2022
-4.26 base
Jan 1, 2023
-4.56 base
Jan 1, 2024
-3.37 base
Jan 1, 2025
-7.62 base
Jan 1, 2026 (e)
-2.07 base
YEARPRICE-TO-EBIT
2026 est -2.07
2025 -7.62
2024 -3.37
2023 -4.56
2022 -4.26
2021 -12.87
2020 -5.30
2019 -3.43
2018 -4.97
2017 -6.85
2016 -57.24
2015 325.34
2014 34.43
2013 40.29
2012 -45.67
2011 17.33
2010 12.53
2009 10.78
2008 -1.00
2007 -0.84
2006 -14.36
Access this data via the Eulerpool API

IRIDEX Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IRIDEX's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IRIDEX's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IRIDEX's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IRIDEX grows earnings faster than its peers.

IRIDEX Stock analysis

What does IRIDEX do? IRIDEX Corp is a global medical technology company that specializes in the development, manufacturing, marketing, and distribution of innovative laser-based medical devices and services. The company was originally founded in 1989 and is headquartered in Mountain View, California. IRIDEX's business model is divided into various divisions, each serving different markets. The divisions include ophthalmology, otolaryngology (ENT), gynecology and urology, as well as scientific research. The company offers a wide range of high-tech laser systems that can be used to treat various conditions, such as retinal diseases, glaucoma, nasal and throat disorders, gynecological and urological conditions, and other medical applications. One of the most well-known divisions of IRIDEX is ophthalmology, which offers a wide range of laser systems for the treatment of retinal diseases. These retinal diseases include diabetic retinopathy, retinal edema, age-related macular degeneration, and retinal detachment. The company also has a high-tech system called Cyclo G6TM, which is used for the treatment of glaucoma. This system can also be used in conjunction with other devices, such as ultrasound systems, for optimized clinical effectiveness. The ENT division offers laser systems for the treatment of nasal and throat disorders, such as snoring, polyps, stenosis, and tumors. The range of laser systems varies from simple systems to advanced systems that can be connected to a flexible endoscope for more precise treatment. IRIDEX's gynecology and urology division offers laser systems for various applications, such as urinary incontinence, bladder problems, tumor removal, prostate tissue removal, and medical treatments to improve sexual function. Laser systems can also be used in combination with other medical devices, such as ultrasound systems. The company places great emphasis on scientific research and development to create and introduce innovative technologies to the market. Therefore, IRIDEX collaborates closely with various research institutes, universities, and medical professionals to further develop its technological advances. The company is also committed to providing comprehensive training and support to its customers to ensure that they use the devices safely and effectively. Overall, IRIDEX Corp has established itself as an innovative and powerful multinational company in the field of medical technology. The company is constantly striving to expand its range of products and services and impress its customers with its high-quality solutions. IRIDEX is confident that it will continue to play a significant role in the medical technology industry in the future. IRIDEX is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IRIDEX stock

EV/EBIT (Enterprise Value to EBIT) of IRIDEX is -8.96 in 2026.

EV/EBIT (Enterprise Value to EBIT) of IRIDEX changed from -2.77 to -8.96, representing a 222.91% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IRIDEX since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IRIDEX with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — IRIDEX

All Key Metrics — IRIDEX